Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029713 (
immaturity
)
4,335
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The pharmacokinetics of gentamicin in premature newborns is influenced by many noncalculable variables. Nevertheless, and despite its narrow therapeutic range, this aminoglycoside antibiotic is usually prescribed according to a fixed schedule.
Gentamicin
was monitored in 22 severely sick, low-birth-weight newborns on combination therapy of various antibiotics including gentamicin. Dosage regimen of gentamicin was prescribed according to Eichenwald and McCracken [1978]. Serum gentamicin concentrations were measured by radioimmunoassay before infusion, 30 min after, and 3 h after infusion of the antibiotic. In 22 prematures desirable serum gentamicin concentrations with a mean elimination half-life (t 1/2) of 5.3 h; in 2 prematures, levels with a mean t 1/2 of 2.3 h; in 7 prematures, possible toxic levels with a mean t 1/2 of 8.3 h; and in 2 prematures, definite toxic levels with a prolonged t 1/2 up to 17 h were observed. Most of the prematures with possible or definite toxic gentamicin levels were not older than 1 week. This is explained by the
immaturity
of the kidneys and the retention of aminoglycosides. A satisfactory correlation between postnatal age and gentamicin elimination half-life was found, which might be caused by postnatal maturation of the glomerular function. In prematures in the 1st postnatal week we recommend reducing the daily dose by prolonging the dosage interval, e.g., from 12 to 18 h, or reducing the single gentamicin doses.
Gentamicin
monitoring seems advisable for detecting toxic serum concentrations and accumulation and for revealing an insufficient dosage of this aminoglycoside antibiotic.
...
PMID:Gentamicin monitoring in low-birth-weight newborns. 662 40